Oh, aspirin prophylaxis study: 1% lower mortality [p=0.95] and 12% fewer cases [p=0.04] https://c19p.org/oh2
copied to clipboard
Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
et al., Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577
Retrospective database analysis of 328,374 adults in South Korea, showing lower risk of COVID-19 cases with aspirin use, but no difference in mortality for COVID-19 patients.
|
risk of death, 1.0% lower, OR 0.99, p = 0.95, adjusted per study, multivariable, RR approximated with OR.
|
|
risk of case, 12.0% lower, RR 0.88, p = 0.04, adjusted per study, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Oh et al., 6/17/2021, retrospective, database analysis, South Korea, Asia, peer-reviewed, 4 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.